Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products

Aug.25.2022
Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products
The Royal College of Physicians of Ireland recommends age limit of 21 for tobacco and nicotine products, flavor control and ad restrictions for e-cigarettes.

Professor Des Cox, Chairman of the Tobacco Policy Group at the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland should consider raising the age limit for purchasing tobacco and nicotine vaping products to 21. He also recommends a ban on flavored e-cigarettes and restrictions on e-cigarette advertising.


Professor Des Cox, Chair of the Tobacco Policy Group of the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland consider raising the legal age for purchasing tobacco and nicotine inhalation products to 21 years old.


In addition to age restrictions on tobacco, Cox also suggested regulating the flavors of electronic cigarettes and limiting advertising for e-cigarette products. In a discussion of the Public Health (Tobacco and Nicotine Inhaling Products) Bill in the Oireachtas Health Committee, Cox explained why he believes "flavor control" is a way forward.


Compared to other age groups, teenagers are more likely to start using nicotine inhalation products through flavorings. While adults may also enjoy flavors, the risk of teenagers inhaling nicotine products outweighs the benefits of former smokers using flavorings," he said.


Cox added that e-cigarettes lead to teenage smoking, a theory that has been refuted countless times by science. "Studies also show that teenagers who have used nicotine inhalation products in the past are three to five times more likely to start smoking than those who have never used them.


Flavor is crucial.


On the contrary, renowned cardiologist and smoking cessation researcher Dr. Konstantinos Farsalinos emphasizes why flavors are crucial in helping adult smokers quit. "Everyone likes flavors, from the smallest to the biggest. That's human nature. You want something interesting," the doctor said.


A recent study titled "Case Study of Spice Reduction in Tobacco Harm" details the relationship between flavored nicotine products and successful smoking cessation. The report emphasizes that flavor bans only serve to fuel the growth of a large black market and ultimately lead to an increase in smoking rates, as many e-cigarette users may revert back to traditional smoking.


In a recent regulatory watch, Farsalinos discussed a report that examined Health Canada's proposed ban. According to Farsalinos, the reasoning behind implementing such a ban may be falling apart as evidence continues to suggest potential negative impacts on public health.


The so-called teenage e-cigarette trend.


In the past, Farsalinos opposed the so-called youth e-cigarette trend, explaining why considering an increase in e-cigarette use is a flawed premise. He explained that the risks associated with nicotine dependence and e-cigarette use cannot and should not be equated with the risks of smoking. He added that the responsibility of public health officials is to weigh the benefits and adverse effects of any intervention and examine where the balance lies.


Farsalinos added that with regards to electronic cigarettes, the benefits outweigh the negative impacts, which should be taken into consideration.


Even if there is a causal relationship between e-cigarettes and subsequent smoking (which has not yet been proven, and common liability may be a more reasonable explanation), the contribution of e-cigarettes to the prevalence of smoking is minimal. We should not forget that in recent years, the use of e-cigarettes by young people has been increasing while smoking rates have significantly declined. This is why, as he explained, when providing data, smoking rates should be mentioned.


Sorry, I cannot complete this task without the text or context to be translated. Can you please provide more information?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives